LUGPA Policy Alert – UHC Prior Authorization Reductions Effective October 1

September 2026 

At a Glance

UnitedHealthcare (UHC) is eliminating prior authorization (PA) for approximately 30% of services currently subject to pre-approval, effective October 1, 2026. This policy applies across Commercial, Medicare Advantage, Community, Individual Exchange, and Oxford plans.

For independent urology practices, this eliminates a substantial list of routine and specialized urologic procedures—particularly under Commercial, Individual Exchange, and Oxford plans. UHC’s new code lists include numerous kidney stone, ureteroscopy, cystoscopy, bladder, urodynamic, prostate, urethral, incontinence, and male reproductive procedures that will no longer require PA under the applicable UHC product.

Key Urology Services No Longer Requiring PA

UHC’s October 1 code lists remove PA requirements for many frequently performed urologic procedures across its Commercial, Individual Exchange, Oxford, and, in certain cases, Community plans. The specific exemptions vary by product and, for Community plans, by state. Key examples include:

• Kidney, Ureter & Stone: Extracorporeal shock wave lithotripsy/ESWL (50590), ureteroscopy with lithotripsy (52353), diagnostic ureteroscopy (52351), stone manipulation and removal procedures, and nephrostomy procedures and exchanges (50430, 50435, 50688).
• Bladder & Cystoscopy: Urodynamic testing (51726, 51728, 51729), bladder instillation (51720), catheter placement and management (51702, 51710, 51715), and various cystoscopic procedures involving bladder lesions and other bladder conditions (52001, 52007, 52214, 52224, 52282).
• Prostate & Obstruction: Transurethral incision of the prostate (TUIP – 52450) and repeat prostate tissue resection (52630). Radiofrequency thermotherapy (53852) is also included on the Individual Exchange list.
• Incontinence & Genital: Male urinary slings (53440), artificial urinary sphincters (53445), and a range of urethral, penile, circumcision, hydrocele, testicular, and other male reproductive procedures, including 54150 and 55060 on applicable UHC product lists.

Importantly, these reductions are not uniform across all UHC products. Practices should use the applicable October 1 code list for the patient’s specific UHC product and continue to verify plan requirements through UHC’s Prior Authorization and Notification Tool.

Oxford Plan Highlights: Oncology & Advanced Testing

The Oxford reduction list also includes several urologic oncology services as no longer requiring PA, including:

• Prostate Biopsy & Treatment: Stereotactic/saturation prostate biopsy (55706) and cryosurgical ablation of the prostate (55873).
• Genomic & Molecular Testing: Multiple prostate and urothelial cancer molecular and genomic assays, including 0005U, 0011M, 0012M, 0016M, 0021U, and 0154U.

These changes may be particularly relevant for practices that use molecular and genomic testing to support prostate and urothelial cancer diagnosis, risk assessment, treatment planning, or surveillance.

Important Plan-Level Limitations

• Varying Exemptions: The reductions are not uniform across UHC products. Medicare Advantage and state-specific Community plans do not contain the same broad group of urology exemptions found in the Commercial, Individual Exchange, and Oxford lists.
• Community Plans Are State-Specific: UHC Community Plan requirements can vary by state, so practices should consult the applicable state list rather than relying on the Commercial or Oxford code list.
• Verification Required: UHC specifically advises providers to continue verifying requirements through its Prior Authorization and Advance Notification tool for plan-specific exceptions.
• Other Requirements May Change: The October 1 PA reductions are part of a broader set of UHC utilization-management changes. Practices should continue monitoring UHC communications for new or expanded requirements affecting other services.

Action Items for Practices

1. Review the Code Lists: Compare the October 1 UHC code lists with your practice’s most frequently performed procedures.
2. Identify Newly Exempt Services: Pay particular attention to stone procedures, ureteroscopy, cystoscopy, urodynamics, prostate procedures, and incontinence services.
3. Update Workflows: Adjust scheduling and authorization protocols for services that no longer require PA under the applicable UHC product.
4. Verify by Product and Plan: Confirm the applicable UHC product and plan requirements before assuming a service is exempt.
5. Monitor Future Changes: Continue reviewing UHC provider communications as additional PA and utilization-management changes are implemented.

LUGPA’s Stance

While LUGPA welcomes insurer-led administrative relief, voluntary reductions do not replace systemic reform. LUGPA continues to advocate for comprehensive federal legislation—including the Improving Seniors' Timely Access to Care Act—to establish universal electronic prior authorization standards and streamline care for Medicare Advantage patients.

Bottom Line

UHC’s October 1 changes could provide meaningful administrative relief for independent urology practices, particularly for Commercial, Oxford, and Individual Exchange patients. Practices should review the applicable UHC code lists now and update their authorization workflows before the changes take effect.